RARE · Ultragenyx Pharmaceutical Inc. · Documents
$16.08
+0.43 (+2.75%)
At close · Oct 26
Return incl. dividend (before tax)
Market Cap
$1.54B
Shares
98.59M
Volume · Oct 26
3.02M
Avg daily vol (3M)
4.12M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Ultragenyx and Baylor Research Institute settled patent litigation with Navinta over DOJOLVI, granting Navinta a non-exclusive, royalty-free license to market a generic version beginning January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted. Similar ANDA litigation remains pending. | 2026-10-19 | — | |
| 8-K | Ultragenyx Pharmaceutical Inc. agreed on October 8, 2026 to sell a Rare Pediatric Disease Priority Review Voucher for $203 million in cash upon closing, subject to customary closing conditions. | 2026-10-14 | 2026-10-08 | |
| 8-K | Ultragenyx Pharmaceutical Inc. agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million in cash at closing; 20% of gross proceeds will be paid to the U.S. Department of Health after closing. | 2026-10-07 | 2026-10-06 | |
| Investor Event Transcript | — | 2026-09-17 | 2026-09-30 | |
| 8-K | — | 2026-09-17 | — | |
| 8-K | — | 2026-09-02 | — | |
| Investor Event Transcript | — | 2026-08-19 | 2026-09-30 | |
| 8-K | — | 2026-08-19 | — | |
| 8-K | — | 2026-08-11 | 2026-08-07 | |
| 10-Q | — | 2026-08-05 | 2026-06-30 | |
| 8-K | — | 2026-08-04 | — | |
| Investor Event Transcript | — | 2026-06-09 | 2026-06-30 | |
| 8-K | — | 2026-05-18 | 2026-05-14 | |
| Investor Event Transcript | — | 2026-05-12 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-12 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-12 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-12 | 2026-06-30 | |
| 10-Q | — | 2026-05-06 | 2026-03-31 | |
| 8-K | — | 2026-05-05 | — | |
| DEFA14A | — | 2026-04-30 | — | |
| 8-K | — | 2026-04-02 | — | |
| 8-K | — | 2026-03-30 | — | |
| DEFA14A | — | 2026-03-27 | — | |
| ARS | — | 2026-03-27 | 2025-12-31 | |
| DEF 14A | — | 2026-03-27 | 2026-05-14 | |
| 8-K | — | 2026-03-12 | — | |
| Investor Event Transcript | — | 2026-03-10 | 2026-03-31 | |
| 8-K | — | 2026-02-23 | — | |
| 10-K | — | 2026-02-18 | 2025-12-31 | |
| 8-K | — | 2026-02-12 | — | |
| 8-K | — | 2026-02-03 | — | |
| 8-K | — | 2026-01-30 | — | |
| 8-K | — | 2026-01-12 | — | |
| 8-K | — | 2025-12-30 | — | |
| 8-K | — | 2025-12-29 | — | |
| 10-Q | — | 2025-11-05 | 2025-09-30 | |
| 8-K | — | 2025-11-04 | 2025-11-03 | |
| 8-K | — | 2025-10-30 | — | |
| 8-K | — | 2025-09-08 | — | |
| 8-K | — | 2025-08-18 | — | |
| 10-Q | — | 2025-08-06 | 2025-06-30 | |
| 8-K | — | 2025-08-05 | — | |
| 8-K | — | 2025-07-31 | — | |
| 8-K | — | 2025-07-11 | — | |
| 8-K | — | 2025-07-09 | — | |
| 8-K | — | 2025-06-27 | — | |
| 8-K | — | 2025-05-19 | 2025-05-15 | |
| 10-Q | — | 2025-05-07 | 2025-03-31 | |
| 8-K | — | 2025-05-06 | — | |
| DEF 14A | — | 2025-03-28 | 2025-05-15 |
Showing 1–50 of 171 filings
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
26 filings
26 filers
Visit website
Investor relations